← Back

Sichuan Jinshi Technology Co Ltd Class A

Sichuan Jinshi Technology Co., Ltd. has no significant operations at present. It intends to pursue business through asset restructuring or expansion into new businesses. The company previously engaged in the research, development, production, and sale of cigarette labels and packaging printed materials. Incorporated in 2008 and headquartered in Chengdu, China, it operates as a subsidiary of Elegant Time Holdings Limited.

Price · split & dividend adjusted
News & notes moving 002951.CS
002951.CS

Jinshi Yayao's 2026 interim net profit reaches 95.4742 million yuan

Jinshi Yayao released its 2026 interim report, with total operating revenue of 491 million yuan, down 0.22% year-on-year, and net profit attributable to the parent company of 95.4742 million yuan. Net cash inflow from operating activities was 107 million yuan, down 27.26% year-on-year. The company's asset-liability ratio was 15.80%, gross margin was 60.52%, ROE was 3.65%, and diluted earnings per share was 0.24 yuan. Total asset turnover was 0.15 times, and inventory turnover was 0.93 times. The number of shareholders was 29,100, and the top ten shareholders held 52.52% of the total share capital.
Sichuan Jinshi…
002951.CS · Capital · Neutral Interim report shows flat revenue and lower operating cash flow, but positive net profit.
Read original ↗
Jiemian·40dRead more →
002951.CS▼

Jinshi Technology reports net loss of 4.97 million yuan in 2026 interim report

Jinshi Technology released its 2026 interim report, with net profit attributable to the parent company at negative 4.97 million yuan. The company's total operating revenue was 86.9986 million yuan, down 64.13% year-on-year, a decrease of 156 million yuan. Net cash flow from operating activities was negative 60.8521 million yuan. The latest asset-liability ratio was 23.03%, gross margin was 21.87%, and ROE was negative 0.33%.
Sichuan Jinshi… ▼
002951.CS · Capital · Negative Reports net loss and 64% revenue decline in interim report.
Read original ↗
Jiemian·42dRead more →
002951.CS▲

Jinshi Asia Pharmaceutical Subsidiary Dier Pharmaceutical's Diclofenac Sodium Sustained-Release Tablets Proposed for Centralized Procurement

Jinshi Asia Pharmaceutical's wholly-owned second-tier subsidiary, Zhejiang Dier Pharmaceutical Co., Ltd., has had its diclofenac sodium sustained-release tablets proposed for selection in the 12th round of national centralized drug procurement. The proposed selected product generated sales revenue of 6.2231 million yuan in 2025 for the same specification, accounting for 0.60% of the company's 2025 operating revenue. Total 2025 sales revenue for the full diclofenac sodium sustained-release tablet category was 38.1834 million yuan, representing 3.68% of the company's 2025 operating revenue. In the first quarter of 2026, Jinshi Asia Pharmaceutical achieved revenue of 331 million yuan and net profit attributable to the parent company of 116 million yuan.
Sichuan Jinshi… ▲
Zhejiang Dier Pharmaceutical Co., Ltd. · Demand · Positive Dier Pharmaceutical's product proposed for selection in centralized procurement, boosting demand.
002951.CS · Demand · Positive Subsidiary's product selected in national procurement, likely to increase sales.
Read original ↗
财中社·63dRead more →
002951.CS▼

Jinshi Yayao Waives Pre-emptive Rights in Lingye Pharma Capital Increase, Stake Passively Diluted to 30.12%

Jinshi Yayao announced that the company has waived its pre-emptive subscription rights in the current capital increase of its associate, Hangzhou Lingye Pharmaceutical Technology Co., Ltd. Lingye Pharma plans to introduce a new strategic investor, Lishui Green Industry Development Fund Co., Ltd., with a capital increase of 40 million yuan and an addition of 1.01 million yuan in registered capital. Before the capital increase, Jinshi Yayao held a 32.43% stake in Lingye Pharma. After the capital increase, its shareholding will be passively diluted to 30.12%. The company's waiver of pre-emptive subscription rights in this capital increase constitutes a related-party transaction.
Sichuan Jinshi… ▼
002951.CS · Capital · Negative Waived pre-emptive rights in associate's capital increase, leading to passive dilution of stake from 32.43% to 30.12%.
杭州领业医药科技有限公司 · Capital · Positive Lingye Pharma is receiving a 40 million yuan capital increase from a new strategic investor.
丽水市绿色产业发展基金有限公司 · Capital · Positive As the new strategic investor, Lishui Green Industry Development Fund is investing 40 million yuan in Lingye Pharma.
Read original ↗
财中社·80dRead more →
002951.CS▼

Jinshi Technology: Supercapacitor Business Has No Orders on Hand for Now

Jinshi Technology, which hit the daily limit up for two consecutive days, issued a stock trading abnormality announcement stating that its supercapacitor business is still in the early development stage, with a relatively low proportion of overall revenue, and currently has no orders on hand. There is still uncertainty as to whether this business can bring good performance returns to the company in the future. The company also stated that it is not involved in liquid cooling related business or optical communication business at present.
Sichuan Jinshi… ▼
002951.CS · Demand · Negative Supercapacitor business has no orders on hand, indicating lack of customer demand.
Read original ↗
证券时报·89dRead more →
© 2026 MarketDXAsset